期刊文献+

间歇性肿瘤细胞减灭术治疗晚期卵巢上皮性癌治疗中的疗效探讨

Curative Effect Observation of Intermittent Cytoreductive Surgery in the Treatment of Epithelial Ovarian Cancer
原文传递
导出
摘要 目的:探讨间歇性肿瘤减灭术在晚期卵巢上皮性癌治疗中的临床价值。方法:将我院收治的68例卵巢上皮性癌患者随机分为观察组和对照组,观察组采用间歇性肿瘤减灭术治疗,对照组采用辅助化疗治疗,对比两组患者的治疗前后的临床特征及术后生存状况。结果:观察组的手术时间、住院时间、术中出血量明显优于对照组,术后3年生存率和5年生存率明显高于对照组。结论:间歇性肿瘤细胞减灭术提高卵巢上皮性癌的治疗效果,延长患者生命,具有较高的临床应用价值。 Objective To explore the clinical value of intermittent cytoreductive surgery in the treatment of epithelial ovarian cancer .Methods Patients with epithelial ovarian cancer were divided into observation group and control group , patients in observation group were cured with intermittent cytoreductive surgery , while patients control group were treated with adjuvant chemotherapy , clinical features and postoperative survival status were com-pared after treatment .Results Operative time, hospital stays and intraoperatve blood loss of the observation group were significantly than control group , survival rate of 3 and 5 years after operation were significantly higher than control group .Conclusion Intermittent cytoreductive surgery could improve of clinical effect of patients with epi-thelial ovarian cancer , meanwhile , it could prolong the life of patients , so intermittent cytoreductive surgery have superior value in the treatment of epithelial ovarian cancer .
出处 《晓庄学院学报(医学版)》 2014年第4期71-73,共3页 Journal of Hunan Normal University(Medical Sciences)
关键词 间歇性肿瘤细胞减灭术 卵巢上皮性癌 疗效观察 intermittent cytoreductive surgery epithelial ovarian cancer clinical effect observation
  • 相关文献

参考文献9

二级参考文献81

  • 1管忠震,徐瑞华.奈达铂临床研究进展[J].中国肿瘤临床,2004,31(13):774-780. 被引量:176
  • 2陈洁.血小板计数与晚期上皮性卵巢癌患者疾病进程和二次开腹探查结果的关系[J].国外医学(妇产科学分册),2005,32(2):130-130. 被引量:4
  • 3杜俊瑶,辛彦.芹菜素抑制人卵巢癌CAOV3细胞增殖的研究[J].中国实用妇科与产科杂志,2007,23(5):374-375. 被引量:18
  • 4Shapiro JD,Millward MJ,Rischin D,et al.Activity of gemcitabine in patients with advanced ovarian cancenresponses seen following platinum and paclitaxe[J].Gynecol Oncol,1996,63(1):89-93.
  • 5Markman M.Second line treatment of ovarian cancer with singleagent gemcitabine[J].Semin Oncol,2002,29(l Suppl l):9-10.
  • 6Coenen M,Berteloot P,Ament F,el at Gemcitabine in platin-paclitaxel resistant ovarian cancer[J].Proc Annu Meet Am Soc Clin Oncol,2000,19:A1603-A1615.
  • 7Bookman MA.Gemcitabine monotherapy in recurrent ovarian cancer:from the bench to the clinic[J].Int J Gynecol Cancer,2005,15(Suppl 1):12-17.
  • 8Pfisterer J.Plante M,Vergote I,et al.Gemcitabine/carboplatin(GC) vs carboplatin(C) in platinum sensitive recurrent ovarian cancer (OVCA):results of a Gynecologic Cancer Intergroup randomized phase Ⅲ trial of the AGOOVAR,the NCICCT Gand the EORTCGCG[J].Proc Am Soc Clin Oncol,2004,449:5005.
  • 9Moufarij MA,Phillips DR,Cullinane C.Gemcitabine potentiates cisplatin cytotoxicity and inhibits repair of cisplatin DNA damage in ovarian cancer cell lines[J].Mol Pharmacol)2003,63(4):862-869.
  • 10Heike Y.Takahashi M.Ohira T,et al.In vivo screening models of cisplatin-resistant human lung cancer cell lines using SCID mice[J].Cancer Chemother Phamacol,1995,35(3):200-204.

共引文献28

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部